|
業務類別
|
Biotechnology |
|
業務概覽
|
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technologyis composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors. |
| 公司地址
| 3 Columbus Circle 15th Floor, New York, NY, USA, 10019 |
| 電話號碼
| +1 646 427-2727 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.indaptusrx.com |
| 員工數量
| 5 |
| Dr. Michael J. Newman, PhD |
Chief Scientific Officer |
美元 363.06K |
27/02/2026 |
| Mr. Junyi Dai |
Chief Executive Officer and Chairman of the Board |
-- |
24/03/2026 |
| Mr. Yu Ding |
Chief Financial Officer |
-- |
03/04/2026 |
|
|
| Mr. David Natan |
Independent Director |
08/01/2026 |
| Mr. Jerome D. Jabbour, J.D. |
Independent Director |
27/02/2026 |
| Mr. Junyi Dai |
Chief Executive Officer and Chairman of the Board |
24/03/2026 |
| Mr. Qinglai Lu |
Independent Director |
03/04/2026 |
| Mr. Tim Ruan |
Independent Director |
23/04/2026 |
| Dr. Yi Zhang |
Independent Director |
23/04/2026 |
|
|
|
|
